Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.
This clinical trial compares the effectiveness and safety of hydrocolloid dressings versus petroleum ointment in post-surgical scar healing, emphasizing patient comfort and cosmetic outcomes.
This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-c
The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases afte
The MERLIN_001 study validates a combined clinicopathological and gene expression profile test that accurately predicts sentinel lymph node metastasis risk in patients with cutaneous melanoma, potentially guiding safer, more personalized su
Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.
A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.
A large international study identified key prognostic markers affecting survival in advanced-stage mycosis fungoides and Sézary syndrome, enabling risk stratification and guiding clinical management.
Large-cell transformation in mycosis fungoides marks an aggressive disease subset with distinct prognostic groups and poor survival, highlighting the need for tailored treatment and integration into staging systems.
The CLIPI prognostic index refines risk stratification in advanced mycosis fungoides and Sézary syndrome, identifying distinct survival groups to guide personalized treatment decisions and improve outcomes.
ICONIC-ADVANCE 1 & 2 phase 3 trials demonstrate that once-daily oral icotrokinra significantly improves skin clearance with superior efficacy and favorable safety compared to placebo and deucravacitinib in moderate-to-severe plaque psor
The IL23R1142G>A genetic variant strongly predicts paradoxical psoriasis in inflammatory bowel disease patients undergoing anti-TNFα therapy, guiding personalized treatment decisions.
This systematic review highlights patient and caregiver priorities in chronic urticaria treatment, emphasizing rapid symptom relief, long-term effectiveness, and safety.
AI demonstrates high accuracy in identifying mpox and other anogenital conditions from clinical images, yet significant research gaps and validation needs remain before clinical adoption.
A recent survey reveals that Australian dermatologists are cautiously integrating AI into practice, prioritizing accuracy and trust for diagnostic use, with optimism about AI enhancing patient access and reducing workload but concerns about
A 16-week Mediterranean diet intervention significantly reduced psoriasis severity and improved metabolic markers in patients with mild to moderate disease, suggesting diet’s role as adjunctive therapy in psoriasis management.
In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psorias
A recent multicenter trial demonstrates that a single dose of benzathine penicillin G is noninferior to three doses in treating early syphilis, including patients with HIV, simplifying management and reducing adverse effects.
Patients with hidradenitis suppurativa face a higher risk of first-time depression and anxiety, regardless of disease severity, highlighting the need for comprehensive psychiatric care.
A large pragmatic trial demonstrates that daily emollient application starting before 9 weeks of age significantly reduces the risk of atopic dermatitis by 24 months in infants not selected for high risk, offering a feasible preventive appr
Open language-specific specialty feeds and department pages.